Webcast scheduled for Wednesday, November 6 at 11:30 a.m. Eastern TimeCARLSBAD, Calif., Oct. 23, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, November 6th at 11:30 a.m. Eastern Time to discuss its third quarter 2024 financial results.The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. About Ionis Pharmaceuticals, Inc.Fo ...

- Recommendation based on NEURO-TTRansform Phase 3 results showing WAINZUA demonstrated consistent and sustained benefit improving neuropathy impairment and quality of life versus placeboCARLSBAD, Calif., Oct. 21, 2024  /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Ionis' and AstraZeneca's WAINZUA (eplontersen) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP) in the European Union (EU) for the treatment of hereditary transthyret ...

– Data continue to demonstrate donidalorsen potential to deliver significant and sustained reductions in HAE attacks up to three years with monthly or every two-month dosing CARLSBAD, Calif., Oct. 3, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will present new three-year data from the Phase 2 open-label extension (OLE) study as well as additional results from the pivotal Phase 3 OASIS and OASISplus studies of donidalorsen, the company's investigational RNA-targete ...

Ionis Pharmaceuticals (IONS) announced that it is floating a secondary issue of 11.5 million shares of its common stock to the public at an issue price of $43.50 per share, amounting to nearly $500.3 million. The company also granted an option to underwriters of the issue to purchase an additional 1.725 million shares at the same price. The secondary offering is expected to close today. Buy Why Did IONS Stock Fall? Ionis' shares fell more than 12% on Tuesday after the announcement. Though the issue does not ...

CARLSBAD, Calif., Sept. 9, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the pricing of an underwritten public offering of 11,500,000 shares of its common stock. The shares of common stock are being sold at a public offering price of $43.50 per share. The aggregate gross proceeds to Ionis from this offering are expected to be approximately $500.3 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Ionis. Ionis ha ...

CARLSBAD, Calif., Sept. 9, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced a proposed underwritten public offering of $500.0 million of its common stock. Ionis intends to grant the underwriters a 30-day option to purchase up to an additional $75.0 million of shares of its common stock offered in the public offering on the same terms and conditions. Ionis intends to use the net proceeds from the offering to fund its independent commercial launches, late-stage clinical programs ...

California-based Ionis Pharmaceuticals (IONS) is focused on the discovery and development of RNA-targeted therapies using its proprietary platform for itself and its partners. It uses this technology to generate a broad pipeline of medicines, targeting neurological, cardiovascular and specialty rare diseases. Despite marketing no wholly-owned drug in its portfolio, IONS enjoys a diverse stream of revenues, including commercial products and royalties and numerous sources of collaborative and R&D revenues. Th ...

kemalbas Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is a biopharmaceutical company specializing in RNA-targeted therapies. It uses antisense DNA technology to design drugs that regulate the production of specific proteins to treat neurological and cardiometabolic diseases, directly addressing their root causes. The company presents an extensive pipeline with partnered and in-house drug developments to address several conditions. It also collaborates with major pharmaceutical companies like Biogen (BIIB), Ast ...

Ionis Pharmaceuticals (IONS) incurred a loss of 45 cents per share for second-quarter 2024, which was narrower than the Zacks Consensus Estimate of a loss of 95 cents per share. Earnings include compensation expenses related to equity awards. Excluding these special items, adjusted loss per share was 24 cents against a loss of 40 cents per share in the year-ago quarter. Total revenues were $225 million in the second quarter, which beat the Zacks Consensus Estimate of $147.0 million. Revenues rose 20% year o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Title of each class Trading symbol Name of each exchange on which registered Common Stock, $.001 Par Value "IONS" The Nasdaq Stock Market LLC Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commissi ...